- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | TransCode Therapeutics Shares Are Surging Today: What's Going On? | 5 | Benzinga.com | ||
| 07.01. | TransCode Therapeutics regains compliance with Nasdaq | 3 | Seeking Alpha | ||
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 20.12.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.12.24 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial | 95 | PR Newswire | Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2
No significant safety or dose limiting toxicities... ► Artikel lesen | |
| 12.12.24 | Transcode Therapeutics stock hits 52-week low at $6.89 | 2 | Investing.com | ||
| 12.12.24 | Peering Into TransCode Therapeutics' Recent Short Interest | 1 | Benzinga.com | ||
| 06.12.24 | Transcode Therapeutics, Inc. - S-1, General form for registration of securities | 11 | SEC Filings | ||
| 02.12.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.12.24 | Why TransCode Therapeutics (RNAZ) Stock Is Diving | 7 | Benzinga.com | ||
| 02.12.24 | TransCode Therapeutics to execute 1-for-33 reverse stock split on Dec 4 | 2 | Seeking Alpha | ||
| 29.11.24 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split | 201 | GlobeNewswire (Europe) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively treating cancer using RNA... ► Artikel lesen | |
| 27.11.24 | TransCode Therapeutics announces $8M private offering | 3 | Seeking Alpha | ||
| 27.11.24 | TransCode Therapeutics, Inc. Announces $8 Million Private Placement | 2 | GlobeNewswire (USA) | ||
| 25.11.24 | Why Transcode Therapeutics (RNAZ) Stock Is Moving | 2 | Benzinga.com | ||
| 25.11.24 | TransCode Therapeutics to conduct reverse stock split | 14 | Seeking Alpha | ||
| 25.11.24 | TransCode Therapeutics approves reverse stock split | 3 | Investing.com | ||
| 25.11.24 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-33 Reverse Stock Split | 186 | GlobeNewswire (Europe) | BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively treating cancer using RNA... ► Artikel lesen | |
| 25.11.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | 9 | SEC Filings | ||
| 05.11.24 | TransCode Therapeutics maintains Nasdaq listing with conditions | 14 | Investing.com |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 113,50 | +0,80 % | BioNTech-Aktie: Wird 2025 ein gutes Jahr? | Im vergangenen Jahr hat die BioNTech-Aktie nicht gerade mit einer starken Performance geglänzt. Worauf müssen sich Anleger 2025 einstellen? Was spricht für steigende Kurse, was dagegen? Verhaltener... ► Artikel lesen | |
| QIAGEN | 43,595 | -0,34 % | Qiagen schüttet clever aus | Bei Qiagen profitieren Anleger nicht nur von verbesserten fundamentalen Aussichten: Das Unternehmen schüttet erneut Kapital über einen Reverse Stock Split aus - insgesamt 300 Mio. US-Dollar. Die Venloer... ► Artikel lesen | |
| NOVAVAX | 8,789 | +0,09 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| MOLOGEN | - | - | EQS-News: Schutzgemeinschaft der Kapitalanleger e.V.: Inhaber der Anleihe WSV 2017/2015 der Mologen AG (ISIN DE000A2DANN4 / WKN A2DANN) mit Beständen bis zu 5.000 Euro Nominalwert können anteilige Vergütung des Gemeinsamen Vertreters zurückerhalten | Emittent / Herausgeber: Schutzgemeinschaft der Kapitalanleger e.V.
/ Schlagwort(e): Anleihe/Sonstiges
Inhaber der Anleihe WSV 2017/2015 der Mologen AG (ISIN DE000A2DANN4 / WKN... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,857 | -5,30 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| BRAIN BIOTECH | 3,120 | -0,95 % | EQS-DD: BRAIN Biotech AG: Adriaan Moelker, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
16.01.2025 / 11:25... ► Artikel lesen | |
| ORGANOVO | 0,337 | +4,34 % | Organovo, Inc.: Organovo Announces Appointment of Norman Staskey as Chief Financial Officer | SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,220 | +6,73 % | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,560 | 0,00 % | COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization | Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen | |
| GENMAB | 199,00 | -1,14 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for 2024 | Company Announcement Net sales of DARZALEX® in 2024 totaled USD 11,670 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN... ► Artikel lesen | |
| XOMA ROYALTY | 25,000 | -2,34 % | Dividendenbekanntmachungen (03.01.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGRICULTURAL BANK OF CHINA LTD ADR US00850M1027 0,4001 USD 0,3897 EUR AMERICAN EXPRESS COMPANY US0258161092 0,7 USD 0,6818 EUR AUTO... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,000 | -9,71 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series | Marlborough, Massachusetts--(Newsfile Corp. - January 22, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,233 | -2,10 % | T2 Biosystems-Aktie stürzt auf 52-Wochen-Tief von 0,25 US-Dollar | ||
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 8-K, Current Report | ||
| ORAGENICS | 0,295 | 0,00 % | Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO | SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided... ► Artikel lesen |
Das Unternehmen TRANSCODE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 7,110 Euro und damit +1,57 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.
